Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

pany's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the belief that Anadys is well-positioned to create value in the evolving HCV landscape; (ii) Anadys' objective to extend the favorable results seen last year when ANA598 was dosed over 12 weeks with the recently initiated Phase IIb study; (iii) the belief that the ANA598 Phase IIb study should set the stage for Phase III development; (iv) the ability for patients to achieve SVR24 in the ANA598 Phase IIb study; (v) the timing, occurrence and outcome of expected milestone events; and (vi) the plans and expected trial design for advancing ANA773 in development for HCV.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its abil
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014 Deep Research Report on Global ... in-depth research report on the China Linalool market. ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report on ...
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... Ariz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: ... into an agreement,with Abbott Laboratories pursuant to which ... non-recourse promissory note with Abbott issued in,connection with ... title to,the urokinase assets, including the remaining inventory ...
... (NYSE: SGP ) today announced two agreements ... in Europe. These agreements are,in connection with conditions ... its October 2007 clearance of Schering-Plough,s acquisition of ... In two separate agreements, Pfizer and Virbac, ...
... today,announced that on April 22, 2008 its management ... Emerging Business Awards, known as the "Bennies.",BioNanomatrix won ... group of growing entrepreneurial firms in the Philadelphia ... the,award on behalf of the company., The ...
Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2
(Date:8/19/2014)... other science courses are increasingly being asked to ... have a new textbook to help them do ... month by Princeton Press and co-authored by scientists ... Synthesis (NIMBioS), teaches readers about basic mathematical and ... and explain biological phenomena. , Suitable for entry-level ...
(Date:8/19/2014)... LIVERPOOL, UK 19 August 2014: An engineer at ... around, despite not having a brain to communicate with ... at Harvard, Professor L Mahadevan, has developed a mathematical ... traditional view of how these soft bodied animals get ... of the central pattern generator (CPG) which states that ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
Breaking Biology News(10 mins):New textbook introduces undergraduates to mathematics for the life sciences 2Secrets of how worms wriggle uncovered 2
... have elucidated a key mechanism by which cancer cells ... and raw materials required to sustain runaway growth. ... Ludwig Cancer Research study also reveals how the aggressive ... therapies that should disrupt this capabilityknown as the Warburg ...
... animals will choose to steer clear of dirt but their ... risk of disease as a result. A study of ... near to used nesting material and droppings left by other mice. ... opportunity to eat outweighs an increased risk of disease from other ...
... to learn that individual "molecular muscles" within cells respond to ... cells "feel" the environment and appropriately adapt their shapes and ... 20 in the journal Nature Materials , specifically sheds ... internal signals. A computer model the researchers developed, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
PFK-2 car (P-17)...
... contains 5 ml Dynabeads Epoxy (4.5 m). ... (epoxy) reactive groups. Ideal for coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurring within 16-20 ...
LTBP-2 (7B10)...
... [198C679.2.1] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
Biology Products: